Page last updated: 2024-09-05

erlotinib hydrochloride and Adenocarcinoma, Endometrioid

erlotinib hydrochloride has been researched along with Adenocarcinoma, Endometrioid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ikeda, S; Kigure, K; Minegishi, T; Nakamura, K; Nishimura, T; Yamashita, S	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Adenocarcinoma, Endometrioid

Article	Year
Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor. BMC cancer, 2015, Dec-16, Volume: 15 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Endometrioid; Endometrial Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays	2015

Article

Year

Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.

BMC cancer, 2015, Dec-16, Volume: 15

Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Endometrioid; Endometrial Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Xenograft Model Antitumor Assays

2015